In a significant advancement in cancer treatment, doctors have initiated trials for the world’s first mRNA lung cancer vaccine. This vaccine is being developed by the same German company behind the COVID-19 vaccines.
Experts are optimistic that this new treatment could save thousands of lives.
Download the SAN app today to stay up-to-date with Unbiased. Straight Facts™.
Point phone camera here
Lung cancer remains the leading cause of cancer deaths globally, responsible for approximately 1.8 million deaths each year. The new vaccine is being tested on patients with the most common type of lung cancer.
The trial is currently underway at 34 research sites across seven countries, including the U.K., U.S., Germany, and Spain. A U.K. patient, diagnosed earlier this year, was the first to receive the treatment. According to the BBC, his treatment will continue weekly for six weeks, followed by a longer-term schedule over the next year.
The injections are designed to target specific markers found on his cancer cells, a method that has scientists excited about its potential. The new treatment is said to target specifically a person’s immune response, strengthening it. The healthy cells are left alone, which is a major divergence from chemotherapy.
While the trial is still in its early stages, researchers are hopeful. The same mRNA technology that helped combat the worst of the COVID-19 pandemic could now be key in fighting cancer.
